New incident report
Incident Report Number: 2010-3452
Registrant Reference Number: PROSAR Case # 1-23538100
Registrant Name (Full Legal Name no abbreviations): Scotts Canada Ltd.
Address: 2000 Argentia Road, Plaza 5, Suite 101
City: Mississauga
Prov / State: Ontario
Country: Canada
Postal Code: L5N2R7
Human
Country: CANADA
Prov / State: ONTARIO
PMRA Registration No. 27521 PMRA Submission No. EPA Registration No.
Product Name: Ortho Home Defense Max Perimeter Indoor Insect Control Ready-to-Use
Yes
Unknown
Site: Res. - In Home / Rés. - à l'int. maison
Unknown
Data Subject
Sex: Male
Age: >19 <=64 yrs / >19 <=64 ans
System
>24 hrs <=3 days / >24 h <=3 jours
Unknown
Yes
9
Day(s) / Jour(s)
Non-occupational
Contact with treated area
What was the activity? contact with furniture to which product had been applied
Unknown
Skin
Unknown / Inconnu
Unknown / Inconnu
1-23538100- The reporter calls to indicate exposure to an insecticide containing the active ingredient permethrin. The reporter indicates he applied the product to his residential home and inside his vehicle fifteen days prior to the initial contact with the registrant. The reporter indicates he may have sat on furniture with still wet product applied. The caller does not, however, describe a discreet exposure incident. The caller reports two days after the initial application he developed symptoms of nausea, vertigo, and ¿lack of motor control" further described as he "could barely walk". He reports by the following day he was brought to the emergency room by ambulance and reports the doctors contacted regional poison control. The physicians were told by poison control the symptoms seen were inconsistent with exposure to this active ingredient. The reporter indicates he was hospitalized for the next nine days during which time he had blood tests (unspecified), a CT scan and many other unspecified tests all of which were reported to be within normal limits. The caller reports he was given no actual treatment during his stay in the hospital. The caller was advised the symptoms seen would not be expected following routine product use. He was advised of the low order of toxicity and concentration of the product. He was advised of topical symptoms that may be seen following immediately dermal contact and appropriate treatment/decontamination. He was advised to follow with his doctor for further treatment/diagnosis. The reporter did not respond to two separate follow up attempts. No further information is available.
Major